Policy Debate on Public Health
Date: 14 October 2014
Location: Palais des Nations, Room XXV
Moderator: Mr. James Chau, CCTV special contributor and UNAIDS Goodwill Ambassador
Press coverage: IP Watch
Developing domestic pharmaceutical production capabilities is increasingly seen as a priority for many developing countries. Governments have adopted various strategies to develop their local pharmaceutical production capacities. This session examined three modes of investment in these pharmaceutical companies: namely, the state-owned enterprise, companies with joint-public and private ownership, and completely privately owned companies, and examined their respective strengths and weaknesses in meeting important public health objectives such as access to medicines.
Elements for the debate
- What are the dynamics of providing access to medicines in developing countries? Is there scope for public endeavour to facilitate access to medicines, particularly to marginalized sections of the population?
- How can publicly-owned pharmaceutical firms be turned into full-fledged competitors to private sector firms?
- What means, other than private equity, exist to encourage private pharmaceutical firms to take on board public health concerns?
Mr. Mukhisa Kituyi, Secretary-General, UNCTAD (Geneva)
Mr. Michel Sidibé, Executive Director, UNAIDS (Geneva)
- Mr. Nevin Bradford, CEO, Cipla Quality Chemicals – (Uganda)
- Dr. Krisana Kraisintu, Board Member, Government Pharmaceutical Organization (Thailand)
- Mr. Roland Göhde, Chairman of the Board, German Health Care Partnership / Senior Managing Director and Member of the Board, Sysmex Partec GmbH (Germany)
- Mr. Jorge Bermudez, Vice President, Fundação Oswaldo Cruz – Fiocruz (Brazil)
- Dr. Lindiwe Makubalo, Minister at the Permanent Mission of South Africa to the United Nations Offices in Geneva
- Mr. Greg Perry, Executive Director, Medicines Patent Pool (Geneva)
- Mr. Rico Gustav, Network of People Living with HIV – (Netherlands)
- Mr. Juergen Reinhardt, Senior Industrial Development Officer, UNIDO – (Austria)
- Mr. Brian Tempest, Editor, Journal of Generic Medicines / former CEO, Ranbaxy (UK)
- Mr. Frank Schmiedchen, Governmental Director, BMZ (Germany)
- Dr. Zafar Mirza, Director, Public Health, Innovation and IP, WHO